Get the Stockscreener App
26.56
1.37%
-0.37
After Hours:
26.58
0.02
+0.08%
Moderna Inc stock is traded at $26.56, with a volume of 30.65M.
It is down -1.37% in the last 24 hours and down -4.53% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$26.93
Open:
$26.345
24h Volume:
30.65M
Relative Volume:
2.87
Market Cap:
$10.27B
Revenue:
$3.14B
Net Income/Loss:
$-3.36B
P/E Ratio:
-3.0424
EPS:
-8.73
Net Cash Flow:
$-4.03B
1W Performance:
+1.14%
1M Performance:
-4.53%
6M Performance:
-38.32%
1Y Performance:
-82.47%
1-Day Range:
$25.60
$26.81
1-Week Range:
$25.60
$27.85
52-Week Range:
$23.15
$158.82
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
26.56 | 10.16B | 3.14B | -3.36B | -4.03B | -8.73 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
US authorities approve Moderna’s new COVID vaccine Statement - Daily Excelsior
Moderna's new COVID-19 vaccine mNexspike approved by FDA, but there's a limit on who can use it - CBS News
Investors Buy High Volume of Call Options on Moderna (NASDAQ:MRNA) - MarketBeat
FDA OKs new COVID-19 vaccine for 65 and older, others with conditions - upi.com
FDA clears Moderna’s new COVID vaccine, but with limits - BioPharma Dive
FDA approves Moderna's new lower-dose COVID-19 vaccine - Value The Markets
Moderna wins narrower US approval for new COVID vaccine - Eagle-Tribune
mNEXSPIKE becomes Moderna's third FDA-approved product - The Pharma Letter
FDA approves new Moderna COVID-19 vaccine - Axios
FDA approves Moderna’s next-gen Covid vaccine, with limits on most healthy people - Endpoints News
Moderna Wins Narrower US Approval for New Covid Vaccine - Bloomberg
Moderna (MRNA) Gains FDA Approval for New COVID-19 Vaccine - GuruFocus
Moderna wins FDA nod for next-gen COVID shot (MRNA:NASDAQ) - Seeking Alpha
Moderna Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE - Lohud
Universal Beteiligungs und Servicegesellschaft mbH Invests $18.08 Million in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna, Inc. (NASDAQ:MRNA) Shares Sold by California State Teachers Retirement System - MarketBeat
FDA approves Moderna’s next-generation COVID vaccine for adults 65 or older - New York Post
FDA Covid Update: Moderna’s New mNEXSPIKE Vaccine Approved for Seniors - Deccan Herald
US FDA approves Moderna’s next-generation COVID vaccine for adults 65 or older - WKZO
US FDA approves Moderna's next-generation COVID vaccine for adults 65 or older - The Jerusalem Post
New COVID vaccine approved by US FDA: Here's all about it - Times of India
Stock Traders Purchase Large Volume of Moderna Call Options (NASDAQ:MRNA) - Defense World
US FDA approves Moderna's next-gen COVID vaccine for adults 65 or older - The Economic Times
Moderna Receives U.S. FDA Approval For Covid-19 Vaccine Mnexspike - marketscreener.com
Moderna Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE | MRNA Stock News - GuruFocus
Moderna Scores FDA Approval for Superior COVID Vaccine: 13.5% More Effective in 65+ Age Group - Stock Titan
Moderna, Inc. (MRNA) Reports Strong H5 Avian Flu Vaccine Data Despite HHS Funding Cut - MSN
US CDC keeps COVID vaccine option for healthy children - Reuters
Health and Human Service cancels funding to Moderna - The San Joaquin Valley Sun
Pfizer CEO: HHS claims of ‘concealed safety concerns’ on mRNA vaccines are ‘completely inaccurate’ - AOL.com
Moderna Bird Flu Vaccine Funding Canceled - Effingham Radio
Two Sigma Advisers LP Sells 252,800 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
US cancels $590 million contract with Moderna for bird flu shot - Watauga Democrat
HHS pulls funding on bird flu vaccine for humans - MEAT+POULTRY
HHS Cancels $590M Avian Flu Vax - Contract Pharma
Lansforsakringar Fondforvaltning AB publ Makes New Investment in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
HHS cancels Moderna’s $590 million contract for bird flu vaccine - Ponca City News
Trump administration cancels $766 million Moderna contract to fight pandemic flu - The Lawton Constitution
FDA Warns of Heart Risk With Pfizer, Moderna COVID Vaccines - Hematology Advisor
Moderna, Inc. (NASDAQ:MRNA) Holdings Reduced by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat
Lazard Asset Management LLC Sells 11,516 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
HHS cancels $766M in funding for Moderna to develop MRNA vaccine against bird flu - NBC News
Trump administration pulls bird flu, other vaccine funding awarded to Moderna - CBS News
HHS cancels Moderna bird flu vaccine contract - The Iola Register
U.S. Cancels Contract With Moderna to Develop Bird Flu Vaccine - The New York Times
Bird Flu Threat Still Looms, But HHS Just Canceled a Moderna Contract That Could Prepare for It - MedCity News
HHS cancels $766m bird flu vaccine contract with Moderna - Pharmaceutical Technology
Moderna at Bernstein Conference: Strategic Diversification Plans - Investing.com
Is Moderna Stock A Sell After RFK Jr. Yanks Its Bird Flu Vaccine Funding? - Investor's Business Daily
HHS terminates Moderna contract to develop bird flu vaccine - BioPharma Dive
US cancels more than $700 million funding for Moderna bird flu vaccine - Reuters
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):